Tag Archives: announces

HHS announces additional staff appointees

Photo by Stefani Reynolds/Getty Images The Department of Health and Human Services today announced its latest round of appointments under the Biden Administration. These new appointees join the department at a time when their expertise is needed to end the ongoing COVID-19 pandemic, implement President Biden’s American Rescue Plan and restore public trust in the… Read More »

A+ Family Dentistry Announces the Opening of Their Third Location in Sorrento Valley While Providing Free Dental Care Service through “Give Back a Smile Program” – Yahoo Finance

SAN DIEGO, Aug. 15, 2019  /PRNewswire/ — A+ Family Dentistry announced today that in addition to their locations in Poway and San Diego, they’re opening a third office in Sorrento Valley in mid-August.  Founded by Drs. Justene Doan and Roger Tran in 2002, this family owned practice has been providing affordable dental care to the San… Read More »

Wilson Stream Family Dentistry announces new ownership – Daily Bulldog

Dr. Thomas Pastor and his staff. From left to right is Kate Richard RDH, Melissa Vining RDH, Joan Brann Receptionist, Dr. Thomas Pastor DDS, Matraca Bellegarde EFDA, Alicia Wyman DA WILTON – Dr. Thomas Pastor, DDS is excited to announce his new ownership of Wilson Stream Family Dentistry, formally Tyngtown Dental in East Wilton. Pastor… Read More »

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Print this page ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in… Read More »

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns

Print this page DUBLIN–(BUSINESS WIRE)–Dec. 27, 2018– Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for Ravicti (glycerol phenylbutyrate) Oral Liquid to include infants younger than two months of age living with a urea cycle disorder… Read More »